Table 4.
Composition of the formulations and responses obtained in the 23 design for butamben encapsulation, using CrodasolTM HS HP as a surfactant.
| NLC | Factor 1 | Factor 2 | Factor 3 | Response 1 | Response 2 | Response 3 |
|---|---|---|---|---|---|---|
| A: Total Lipids | B: CrodasolTM HS HP | C: Sonication Time | Size | PDI | Zeta Potential | |
| % | % | min | nm | |mV| | ||
| 1 | 10 | 5 | 5 | 244.93 | 0.187 | 25.66 |
| 2 | 20 | 5 | 5 | 328.06 | 0.176 | 29.33 |
| 3 | 10 | 10 | 5 | 361.76 | 0.308 | 26.36 |
| 4 | 20 | 10 | 5 | 698.93 | 0.319 | 26.8 |
| 5 | 10 | 5 | 10 | 267.16 | 0.198 | 29.16 |
| 6 | 20 | 5 | 10 | 442.7 | 0.281 | 27.62 |
| 7 | 10 | 10 | 10 | 364.4 | 0.317 | 25.9 |
| 8 | 20 | 10 | 10 | 589.8 | 0.349 | 29.26 |
| 9 | 15 | 7.5 | 7.5 | 407.23 | 0.253 | 28.16 |
| 10 | 15 | 7.5 | 7.5 | 416.66 | 0.237 | 25.4 |
| 11 | 15 | 7.5 | 7.5 | 406.9 | 0.285 | 25.76 |